Dexamethasone Coanalgesic Administration in Steroid Naïve and Steroid Non-Naïve Patients for the Prevention of Pain Flares after Palliative Radiotherapy for Bone Metastases

Objective. Dexamethasone could be an effective prophylactic agent for the prevention of pain flares after palliative radiotherapy (RT) for uncomplicated bone metastases. To date, there are no data on its prophylactic coanalgesic (opioid-sparing) effect after RT in patients with complicated bone meta...

Full description

Saved in:
Bibliographic Details
Main Authors: Dimitar G. Tonev, Silvia A. Lalova, Elena P. Petkova-Lungova, Nikolay V. Timenov, Gabriela M. Radeva, Todor G. Kundurzhiev
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Pain Research and Management
Online Access:http://dx.doi.org/10.1155/2022/6153955
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832567083117838336
author Dimitar G. Tonev
Silvia A. Lalova
Elena P. Petkova-Lungova
Nikolay V. Timenov
Gabriela M. Radeva
Todor G. Kundurzhiev
author_facet Dimitar G. Tonev
Silvia A. Lalova
Elena P. Petkova-Lungova
Nikolay V. Timenov
Gabriela M. Radeva
Todor G. Kundurzhiev
author_sort Dimitar G. Tonev
collection DOAJ
description Objective. Dexamethasone could be an effective prophylactic agent for the prevention of pain flares after palliative radiotherapy (RT) for uncomplicated bone metastases. To date, there are no data on its prophylactic coanalgesic (opioid-sparing) effect after RT in patients with complicated bone metastases compared to uncomplicated ones, which is the aim of our study. Methods. Twenty-nine American Society of Anaesthesiologists (ASA) III-IV patients, aged ≥18, treated with single-fraction 8 Gy/1 or multi-fraction 20 Gy/5 RT for painful uncomplicated bone metastases (steroid naïve patients, n = 14) or complicated ones (steroid non-naïve patients, n = 15), were examined retrospectively. All patients received parenteral dexamethasone (4 mg or 8 mg daily, 1 hour before RT, followed by the same dose for the next 4 days) along with their background and breakthrough pain opioid intake (morphine equivalents) during their 5-day in-hospital stay. Pain severity (numeric rating scale) and analgesic consumption were recorded at admission, daily during the hospital stay, and for 10 days following treatment. Binary logistic regression was used to determine predictive factors for pain flare occurrence. Results. A higher ASA score is the only determinant positively influencing opioid consumption (P = 0.018) and pain flare as well (OR = 15.00; 95% CI: 2, 24–100, 48; P = 0.005). Lower dose 4 mg dexamethasone was revealed as a moderate analgesic agent in steroid naïve patients with no side effects, whereas in steroid non-naïve patients the predominantly higher dose 8 mg dexamethasone had minimal impact on pain flares prevention at the expense of more pronounced immunosuppression (P = 0.039). Conclusions. Irrespective of the supporting evidence of dexamethasone potential for prevention of RT-induced pain flare, our data failed to reveal its efficacy in the real practice world (a case mix of uncomplicated and complicated bone metastases). Further dose-effect bigger studies are needed, identifying optimal doses of dexamethasone intake and its optimal duration in high-risk patients.
format Article
id doaj-art-23f451e327b049dc8fa79323e79cde6d
institution Kabale University
issn 1918-1523
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Pain Research and Management
spelling doaj-art-23f451e327b049dc8fa79323e79cde6d2025-02-03T01:02:23ZengWileyPain Research and Management1918-15232022-01-01202210.1155/2022/6153955Dexamethasone Coanalgesic Administration in Steroid Naïve and Steroid Non-Naïve Patients for the Prevention of Pain Flares after Palliative Radiotherapy for Bone MetastasesDimitar G. Tonev0Silvia A. Lalova1Elena P. Petkova-Lungova2Nikolay V. Timenov3Gabriela M. Radeva4Todor G. Kundurzhiev5Medical University of SofiaRadiotherapy ClinicRadiotherapy ClinicDepartment of Anesthesiology and Intensive CareMedical University of SofiaMedical University of SofiaObjective. Dexamethasone could be an effective prophylactic agent for the prevention of pain flares after palliative radiotherapy (RT) for uncomplicated bone metastases. To date, there are no data on its prophylactic coanalgesic (opioid-sparing) effect after RT in patients with complicated bone metastases compared to uncomplicated ones, which is the aim of our study. Methods. Twenty-nine American Society of Anaesthesiologists (ASA) III-IV patients, aged ≥18, treated with single-fraction 8 Gy/1 or multi-fraction 20 Gy/5 RT for painful uncomplicated bone metastases (steroid naïve patients, n = 14) or complicated ones (steroid non-naïve patients, n = 15), were examined retrospectively. All patients received parenteral dexamethasone (4 mg or 8 mg daily, 1 hour before RT, followed by the same dose for the next 4 days) along with their background and breakthrough pain opioid intake (morphine equivalents) during their 5-day in-hospital stay. Pain severity (numeric rating scale) and analgesic consumption were recorded at admission, daily during the hospital stay, and for 10 days following treatment. Binary logistic regression was used to determine predictive factors for pain flare occurrence. Results. A higher ASA score is the only determinant positively influencing opioid consumption (P = 0.018) and pain flare as well (OR = 15.00; 95% CI: 2, 24–100, 48; P = 0.005). Lower dose 4 mg dexamethasone was revealed as a moderate analgesic agent in steroid naïve patients with no side effects, whereas in steroid non-naïve patients the predominantly higher dose 8 mg dexamethasone had minimal impact on pain flares prevention at the expense of more pronounced immunosuppression (P = 0.039). Conclusions. Irrespective of the supporting evidence of dexamethasone potential for prevention of RT-induced pain flare, our data failed to reveal its efficacy in the real practice world (a case mix of uncomplicated and complicated bone metastases). Further dose-effect bigger studies are needed, identifying optimal doses of dexamethasone intake and its optimal duration in high-risk patients.http://dx.doi.org/10.1155/2022/6153955
spellingShingle Dimitar G. Tonev
Silvia A. Lalova
Elena P. Petkova-Lungova
Nikolay V. Timenov
Gabriela M. Radeva
Todor G. Kundurzhiev
Dexamethasone Coanalgesic Administration in Steroid Naïve and Steroid Non-Naïve Patients for the Prevention of Pain Flares after Palliative Radiotherapy for Bone Metastases
Pain Research and Management
title Dexamethasone Coanalgesic Administration in Steroid Naïve and Steroid Non-Naïve Patients for the Prevention of Pain Flares after Palliative Radiotherapy for Bone Metastases
title_full Dexamethasone Coanalgesic Administration in Steroid Naïve and Steroid Non-Naïve Patients for the Prevention of Pain Flares after Palliative Radiotherapy for Bone Metastases
title_fullStr Dexamethasone Coanalgesic Administration in Steroid Naïve and Steroid Non-Naïve Patients for the Prevention of Pain Flares after Palliative Radiotherapy for Bone Metastases
title_full_unstemmed Dexamethasone Coanalgesic Administration in Steroid Naïve and Steroid Non-Naïve Patients for the Prevention of Pain Flares after Palliative Radiotherapy for Bone Metastases
title_short Dexamethasone Coanalgesic Administration in Steroid Naïve and Steroid Non-Naïve Patients for the Prevention of Pain Flares after Palliative Radiotherapy for Bone Metastases
title_sort dexamethasone coanalgesic administration in steroid naive and steroid non naive patients for the prevention of pain flares after palliative radiotherapy for bone metastases
url http://dx.doi.org/10.1155/2022/6153955
work_keys_str_mv AT dimitargtonev dexamethasonecoanalgesicadministrationinsteroidnaiveandsteroidnonnaivepatientsforthepreventionofpainflaresafterpalliativeradiotherapyforbonemetastases
AT silviaalalova dexamethasonecoanalgesicadministrationinsteroidnaiveandsteroidnonnaivepatientsforthepreventionofpainflaresafterpalliativeradiotherapyforbonemetastases
AT elenappetkovalungova dexamethasonecoanalgesicadministrationinsteroidnaiveandsteroidnonnaivepatientsforthepreventionofpainflaresafterpalliativeradiotherapyforbonemetastases
AT nikolayvtimenov dexamethasonecoanalgesicadministrationinsteroidnaiveandsteroidnonnaivepatientsforthepreventionofpainflaresafterpalliativeradiotherapyforbonemetastases
AT gabrielamradeva dexamethasonecoanalgesicadministrationinsteroidnaiveandsteroidnonnaivepatientsforthepreventionofpainflaresafterpalliativeradiotherapyforbonemetastases
AT todorgkundurzhiev dexamethasonecoanalgesicadministrationinsteroidnaiveandsteroidnonnaivepatientsforthepreventionofpainflaresafterpalliativeradiotherapyforbonemetastases